PT  - JOURNAL ARTICLE
AU  - Elena Vigliar
AU  - Antonino Iaccarino
AU  - Dario Bruzzese
AU  - Umberto Malapelle
AU  - Claudio Bellevicine
AU  - Giancarlo Troncone
TI  - Cytology in the time of coronavirus disease (COVID-19): an Italian perspective
AID  - 10.1136/jclinpath-2020-206614
DP  - 2021 Apr 01
TA  - Journal of Clinical Pathology
PG  - 261--263
VI  - 74
IP  - 4
4099  - http://jcp.bmj.com/content/74/4/261.short
4100  - http://jcp.bmj.com/content/74/4/261.full
SO  - J Clin Pathol2021 Apr 01; 74
AB  - Introduction The coronavirus disease 2019 (COVID-19) is changing the way we practice pathology, including fine needle aspiration (FNA) diagnostics. Although recommendations have been issued to prioritise patients at high oncological risk, postponing those with unsuspicious presentations, real world data have not been reported yet.Methods The percentages of the cytological sample types processed at the University of Naples Federico II, during the first 3 weeks of Italian national lockdown were compared with those of the same period in 2019.Results During the emergency, the percentage of cytology samples reported as malignant increased (p<0.001), reflecting higher percentages of breast (p=0.002) and lymph nodes FNAs (p=0.008), effusions (p<0.001) and urine (p=0.005). Conversely, thyroid FNAs (p<0.001) and Pap smears (p=0.003) were reduced.Conclusions Even in times of COVID-19 outbreak, cytological examination may be safely carried out in patients at high oncological risk, without the need to be postponed.